Optimizing Treatments for Heart Failure During Hospitalization
NCT ID: NCT05910437
Last Updated: 2023-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-09-30
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).
Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.
The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PAtient Treatment Analysis: Hospital and Wide-ranging Out-of-hospital Care Assessment Yields Insights Into Heart Failure Outcomes
NCT06338878
Readmission in the Case of Patients With Heart Failure
NCT02808221
Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient
NCT01834833
Evaluation of a Back-to-home Support Program for Hospitalized Patients for Heart Failure
NCT05566145
Evaluation of the Program to Help Return Home Patients Hospitalized for Heart Failure, From Paris Saint-Joseph Hospital
NCT04613973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hospitalized patient for decompensated heart failure
Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized (≥24h) for decompensated heart failure in cardiology.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr. Nicolas GIRERD
coordinating investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas GIRERD, MD-PhD
Role: STUDY_CHAIR
CHRU de NANCY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chr Metz Thionville
Ars-Laquenexy, , France
CHRU de NANCY
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Noura ZANNAD, MD
Role: primary
Nicolas GIRERD, MD-PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022PI115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.